| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 1,178,700 | 1,137,870 | 1,043,760 | 880,890 | 1,013,340 |
| Sales Growth | +3.59% | +9.02% | +18.49% | -13.07% | +10.26% |
| Net Income | 201,210 | 106,460 | -444,600 | 169,550 | 201,080 |
| Net Income Growth | +89.00% | +123.95% | -362.22% | -15.68% | +17.41% |
Incyte Corp (INCY)
59.14 x 1 68.00 x 1
Post-market by (Cboe BZX)
60.60 -0.08 (-0.13%) 03/28/25 [NASDAQ]
59.14 x 1 68.00 x 1
Post-market 60.60 unch (unch) 16:20 ET
for Fri, Mar 28th, 2025
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
Fiscal Year End Date: 12/31